CL2012003033A1 - Una asociacion de a) el inhibidor de la xantina oxidasa febuxostat y b) al menos un inhibidor de la hmg coa reductasa pertenecientes a la clase de las estatinas; composicion farmaceutica que los comprende; metodo de preparacion; y uso para tratar la hipercolesterolemia sola o asociada con hiperuricemia y/o hiperglicemia. - Google Patents
Una asociacion de a) el inhibidor de la xantina oxidasa febuxostat y b) al menos un inhibidor de la hmg coa reductasa pertenecientes a la clase de las estatinas; composicion farmaceutica que los comprende; metodo de preparacion; y uso para tratar la hipercolesterolemia sola o asociada con hiperuricemia y/o hiperglicemia.Info
- Publication number
- CL2012003033A1 CL2012003033A1 CL2012003033A CL2012003033A CL2012003033A1 CL 2012003033 A1 CL2012003033 A1 CL 2012003033A1 CL 2012003033 A CL2012003033 A CL 2012003033A CL 2012003033 A CL2012003033 A CL 2012003033A CL 2012003033 A1 CL2012003033 A1 CL 2012003033A1
- Authority
- CL
- Chile
- Prior art keywords
- hyperuricemia
- hyperglycemia
- association
- alone
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Una asociación de A) El inhibidor de la xantina oxidasa febuxostat y B) Al menos un inhibidor de la HMG coa reductasa pertenecientes a la clase de las estatinas; composición farmacéutica que los comprende; método de preparación; y uso para tratar la hipercolesterolemia sola o asociada con hiperuricemia y/o hiperglicemia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2010A000231A IT1400310B1 (it) | 2010-05-10 | 2010-05-10 | Associazione di inibitori della xantina ossidasi e statine e loro uso. |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012003033A1 true CL2012003033A1 (es) | 2013-06-21 |
Family
ID=42753376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012003033A CL2012003033A1 (es) | 2010-05-10 | 2012-10-29 | Una asociacion de a) el inhibidor de la xantina oxidasa febuxostat y b) al menos un inhibidor de la hmg coa reductasa pertenecientes a la clase de las estatinas; composicion farmaceutica que los comprende; metodo de preparacion; y uso para tratar la hipercolesterolemia sola o asociada con hiperuricemia y/o hiperglicemia. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20130116291A1 (es) |
EP (1) | EP2568981A1 (es) |
JP (1) | JP2013526499A (es) |
KR (1) | KR20130079427A (es) |
CN (1) | CN103025329A (es) |
AR (1) | AR081375A1 (es) |
AU (1) | AU2011252193A1 (es) |
BR (1) | BR112012028892A2 (es) |
CA (1) | CA2798707A1 (es) |
CL (1) | CL2012003033A1 (es) |
CO (1) | CO6630144A2 (es) |
CR (1) | CR20120618A (es) |
EA (1) | EA201201529A1 (es) |
IL (1) | IL222926A0 (es) |
IT (1) | IT1400310B1 (es) |
MA (1) | MA34232B1 (es) |
MX (1) | MX2012013052A (es) |
NZ (1) | NZ603397A (es) |
PE (1) | PE20130811A1 (es) |
SG (1) | SG185445A1 (es) |
TW (1) | TW201206430A (es) |
WO (1) | WO2011141387A1 (es) |
ZA (1) | ZA201209294B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112370473A (zh) * | 2020-12-04 | 2021-02-19 | 首都医科大学附属北京朝阳医院 | 他汀组合物及其在制备治疗高尿酸血症药物中的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
AU645867B2 (en) | 1990-11-30 | 1994-01-27 | Teijin Pharma Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
EP1020454B2 (en) | 1998-06-19 | 2013-01-23 | Teijin Pharma Limited | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof |
US20040122067A1 (en) | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
WO2005027887A2 (en) * | 2003-09-17 | 2005-03-31 | Cardimone Pharma Corporation | Methods and compositions for improving endothelial function |
JP5242393B2 (ja) | 2005-08-03 | 2013-07-24 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | 高血圧症の治療方法 |
WO2007044910A1 (en) * | 2005-10-13 | 2007-04-19 | Duke University | Compositions for the treatment and prevention of heart disease and methods of using same |
CA2630639A1 (en) | 2005-11-21 | 2007-05-31 | Tap Pharmaceutical Products, Inc. | Treatment of qt interval prolongation and diseases associated therewith |
KR20160031040A (ko) | 2006-11-13 | 2016-03-21 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 |
-
2010
- 2010-05-10 IT ITRM2010A000231A patent/IT1400310B1/it active
-
2011
- 2011-05-06 CN CN2011800228898A patent/CN103025329A/zh active Pending
- 2011-05-06 US US13/697,062 patent/US20130116291A1/en not_active Abandoned
- 2011-05-06 EP EP11717667A patent/EP2568981A1/en not_active Withdrawn
- 2011-05-06 SG SG2012081808A patent/SG185445A1/en unknown
- 2011-05-06 WO PCT/EP2011/057343 patent/WO2011141387A1/en active Application Filing
- 2011-05-06 KR KR1020127032187A patent/KR20130079427A/ko not_active Application Discontinuation
- 2011-05-06 BR BR112012028892A patent/BR112012028892A2/pt not_active IP Right Cessation
- 2011-05-06 MX MX2012013052A patent/MX2012013052A/es not_active Application Discontinuation
- 2011-05-06 MA MA35369A patent/MA34232B1/fr unknown
- 2011-05-06 AU AU2011252193A patent/AU2011252193A1/en not_active Abandoned
- 2011-05-06 PE PE2012002150A patent/PE20130811A1/es not_active Application Discontinuation
- 2011-05-06 CA CA2798707A patent/CA2798707A1/en not_active Abandoned
- 2011-05-06 NZ NZ603397A patent/NZ603397A/en not_active IP Right Cessation
- 2011-05-06 JP JP2013509522A patent/JP2013526499A/ja not_active Abandoned
- 2011-05-06 EA EA201201529A patent/EA201201529A1/ru unknown
- 2011-05-09 TW TW100116116A patent/TW201206430A/zh unknown
- 2011-05-09 AR ARP110101589A patent/AR081375A1/es unknown
-
2012
- 2012-10-19 CO CO12185573A patent/CO6630144A2/es not_active Application Discontinuation
- 2012-10-29 CL CL2012003033A patent/CL2012003033A1/es unknown
- 2012-11-08 IL IL222926A patent/IL222926A0/en unknown
- 2012-12-06 CR CR20120618A patent/CR20120618A/es unknown
- 2012-12-07 ZA ZA2012/09294A patent/ZA201209294B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL222926A0 (en) | 2012-12-31 |
CO6630144A2 (es) | 2013-03-01 |
JP2013526499A (ja) | 2013-06-24 |
PE20130811A1 (es) | 2013-08-08 |
SG185445A1 (en) | 2012-12-28 |
NZ603397A (en) | 2014-03-28 |
AU2011252193A1 (en) | 2012-11-29 |
MA34232B1 (fr) | 2013-05-02 |
EA201201529A1 (ru) | 2013-04-30 |
US20130116291A1 (en) | 2013-05-09 |
ITRM20100231A1 (it) | 2011-11-11 |
IT1400310B1 (it) | 2013-05-24 |
MX2012013052A (es) | 2013-07-03 |
AR081375A1 (es) | 2012-08-29 |
BR112012028892A2 (pt) | 2016-07-26 |
KR20130079427A (ko) | 2013-07-10 |
WO2011141387A1 (en) | 2011-11-17 |
CR20120618A (es) | 2014-03-21 |
CA2798707A1 (en) | 2011-11-17 |
EP2568981A1 (en) | 2013-03-20 |
CN103025329A (zh) | 2013-04-03 |
TW201206430A (en) | 2012-02-16 |
ZA201209294B (en) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
CL2013001339A1 (es) | Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih. | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CL2012000026A1 (es) | Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus. | |
CL2012000469A1 (es) | Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit. | |
ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2012003657A1 (es) | Formulacion estable que comprende la proteina iduronato -2- sulfatasa y un tensoactivo de polisorbato; contenedor que comprende dicha formulacion; uso de dicha formulacion para tratar sindrome de hunters. | |
CO6351777A2 (es) | Compuestos de tetraciclina sustituidod con fluor en c7 | |
CL2011002675A1 (es) | Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. | |
CL2011002258A1 (es) | Compuestos derivados heterociclicos fusionados; composicion farmaceutica que los comprende; y uso de los compuestos para tratar vih. | |
BRPI0509926A (pt) | imidazóis | |
EP4059935A4 (en) | PYRROLOPYRIMIDINE COMPOUND AS BTK INHIBITOR AND USE THEREOF | |
UY34315A (es) | ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ? | |
CL2012001757A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas. | |
CL2022001736A1 (es) | Nuevos compuestos farmacéuticos | |
ECSP15050273A (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
DOP2010000361A (es) | Dronedarona para la prevencion de la cardioversion | |
CL2014000595A1 (es) | Extracto de cynara; composicion farmaceutica que lo contiene; y su uso para el tratamiento de hiperglucemia, hipercolesterolemia, hipertension y esteatosis hepatica. |